Mirzaten Q-Tab (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten Q-Tab, is a tetracyclic antidepressant presented as a tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to alleviate depressive symptoms by modulating neurotransmitter activity and is classified under ATC code N06AX11.

GNH USA supplies Mirzaten Q-Tab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Mirtazapine is indicated for depressive disorders and works within the serotonergic and noradrenergic pathways to improve mood. - Major depressive disorder: reduction of depressive symptoms in adult patients. - Depressive episodes: improvement of mood and functional status during acute episodes. - Treatment‑resistant depression: option when other antidepressants have not provided adequate response.

Common Side Effects: - Sedation or drowsiness. - Increased appetite and weight gain. - Dry mouth. - Constipation. - Dizziness. - Enhanced cholesterol levels.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Severe hypersensitivity reactions. - Suicidal thoughts or behavior, especially early in therapy. - Serotonin syndrome when combined with other serotonergic agents. - Hepatotoxicity or liver enzyme elevation.

Before initiating therapy, consider the following precautions: - Assess hepatic function: adjust use in severe liver impairment. - Monitor for worsening depression or emergence of suicidal ideation. - Use caution in patients with a history of bipolar disorder or mania. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal risk. - Evaluate risk versus benefit in pregnancy and lactation, as safety data are limited. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Mirtazapine may interact with several drug classes; monitoring is essential. Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Linezolid or other reversible MAO inhibitors. - Other serotonergic agents (e.g., SSRIs, SNRIs) when combined may precipitate serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol) can intensify sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise exposure. - Alcohol: can enhance sedative effects. - Antihistamines: additive drowsiness. - Other antidepressants: may require dose adjustment and close observation.